Brind.

Daiichi Sankyo and AstraZeneca are seeking approval for the Datroway antibody drug conjugate in the European Union, with the EMA opinion currently under review by the European Commission.

3 reports, 1 independent Updated Jul 31
Gone quiet Reached 2 outlets in its first 24 hours
Reports
3
Developments
2
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Daiichi Sankyo and AstraZeneca are seeking approval for the Datroway antibody drug conjugate in the European Union, with the EMA opinion currently under review by the European Commission.

Who's involved

What this event is mainly about
Daiichi SankyoAstraZeneca

How it developed

Newest first. Tap a step to see who reported it.
  1. Daiichi Sankyo and AstraZeneca jointly conducted a Phase III trial of Enhertu for the treatment of NSCLC.Sub-event
  2. Datroway ADC seeking EU approval after EMA opinion review.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
2 more outlets ran the same wire story